Natural Product Hybrids as New Leads for Drug Discovery
Natural products play an important role in the development of drugs, especially for the treatment of infections and cancer, as well as immunosuppressive compounds. However, the number of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products c...
Gespeichert in:
Veröffentlicht in: | Angewandte Chemie International Edition 2003-09, Vol.42 (34), p.3996-4028 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4028 |
---|---|
container_issue | 34 |
container_start_page | 3996 |
container_title | Angewandte Chemie International Edition |
container_volume | 42 |
creator | Tietze, Lutz F. Bell, Hubertus P. Chandrasekhar, Srivari |
description | Natural products play an important role in the development of drugs, especially for the treatment of infections and cancer, as well as immunosuppressive compounds. However, the number of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products can be prepared. This new approach seems to be very promising in the development of leads for both medicinal and agrochemical applications, as the biological activity of several new hybrids exceeds that of the parent compounds. The advantage of this concept over a combinatorial chemistry approach is the high diversity and the inherent biological activity of the hybrids.
Unlimited options: The synthesis of natural product hybrids by combining structurally different, naturally occurring compounds that exhibit high biological activities appears to be a promising approach to increase the number and diversity of substances for pharmacological testing. An example is the hybrid of estrone and (−)‐talaromycin (see picture). |
doi_str_mv | 10.1002/anie.200200553 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73661287</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73661287</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4853-c2f902933ccd5a5fb34de9ba4b45915ab89884bb2cce1dbfb04dfdb17d9639353</originalsourceid><addsrcrecordid>eNqFkElPwzAQRi0EolC4ckQ5cUvxEsfxsRtdiApCII6Wt6BA2hQ7ofTfkypV4cZpZqT3PY0-AK4Q7CEI8a1c5baHmw1CSskROEMUo5AwRo6bPSIkZAlFHXDu_XtDJQmMT0EHYc4Io_wMsIWsaieL4NGVptZVMN0qlxsfSB8s7CZIrWyOrHTByNVvwSj3uvyybnsBTjJZeHu5n13wcjd-Hk7D9GEyG_bTUEcJJaHGGYeYE6K1oZJmikTGciUjFVGOqFQJT5JIKay1RUZlCkYmMwoxw2PCCSVdcNN61678rK2vxLJ5wRaFXNmy9oKROEY4YQ3Ya0HtSu-dzcTa5UvptgJBsatK7KoSh6qawPXeXKulNb_4vpsG4C2wyQu7_Ucn-ovZ-K88bLO5r-z3ISvdh4h3dvG6mAj8NJjfp4O5oOQHpEWD4w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>73661287</pqid></control><display><type>article</type><title>Natural Product Hybrids as New Leads for Drug Discovery</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Tietze, Lutz F. ; Bell, Hubertus P. ; Chandrasekhar, Srivari</creator><creatorcontrib>Tietze, Lutz F. ; Bell, Hubertus P. ; Chandrasekhar, Srivari</creatorcontrib><description>Natural products play an important role in the development of drugs, especially for the treatment of infections and cancer, as well as immunosuppressive compounds. However, the number of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products can be prepared. This new approach seems to be very promising in the development of leads for both medicinal and agrochemical applications, as the biological activity of several new hybrids exceeds that of the parent compounds. The advantage of this concept over a combinatorial chemistry approach is the high diversity and the inherent biological activity of the hybrids.
Unlimited options: The synthesis of natural product hybrids by combining structurally different, naturally occurring compounds that exhibit high biological activities appears to be a promising approach to increase the number and diversity of substances for pharmacological testing. An example is the hybrid of estrone and (−)‐talaromycin (see picture).</description><identifier>ISSN: 1433-7851</identifier><identifier>EISSN: 1521-3773</identifier><identifier>DOI: 10.1002/anie.200200553</identifier><identifier>PMID: 12973759</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>Animals ; biological activity ; Biological Factors - chemistry ; Biological Factors - pharmacology ; combinatorial chemistry ; Drug Design ; Drug Evaluation, Preclinical - methods ; Humans ; hybrids ; Molecular Structure ; natural products ; Pharmaceutical Preparations - chemical synthesis ; Pharmaceutical Preparations - chemistry</subject><ispartof>Angewandte Chemie International Edition, 2003-09, Vol.42 (34), p.3996-4028</ispartof><rights>Copyright © 2003 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4853-c2f902933ccd5a5fb34de9ba4b45915ab89884bb2cce1dbfb04dfdb17d9639353</citedby><cites>FETCH-LOGICAL-c4853-c2f902933ccd5a5fb34de9ba4b45915ab89884bb2cce1dbfb04dfdb17d9639353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fanie.200200553$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12973759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tietze, Lutz F.</creatorcontrib><creatorcontrib>Bell, Hubertus P.</creatorcontrib><creatorcontrib>Chandrasekhar, Srivari</creatorcontrib><title>Natural Product Hybrids as New Leads for Drug Discovery</title><title>Angewandte Chemie International Edition</title><addtitle>Angewandte Chemie International Edition</addtitle><description>Natural products play an important role in the development of drugs, especially for the treatment of infections and cancer, as well as immunosuppressive compounds. However, the number of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products can be prepared. This new approach seems to be very promising in the development of leads for both medicinal and agrochemical applications, as the biological activity of several new hybrids exceeds that of the parent compounds. The advantage of this concept over a combinatorial chemistry approach is the high diversity and the inherent biological activity of the hybrids.
Unlimited options: The synthesis of natural product hybrids by combining structurally different, naturally occurring compounds that exhibit high biological activities appears to be a promising approach to increase the number and diversity of substances for pharmacological testing. An example is the hybrid of estrone and (−)‐talaromycin (see picture).</description><subject>Animals</subject><subject>biological activity</subject><subject>Biological Factors - chemistry</subject><subject>Biological Factors - pharmacology</subject><subject>combinatorial chemistry</subject><subject>Drug Design</subject><subject>Drug Evaluation, Preclinical - methods</subject><subject>Humans</subject><subject>hybrids</subject><subject>Molecular Structure</subject><subject>natural products</subject><subject>Pharmaceutical Preparations - chemical synthesis</subject><subject>Pharmaceutical Preparations - chemistry</subject><issn>1433-7851</issn><issn>1521-3773</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkElPwzAQRi0EolC4ckQ5cUvxEsfxsRtdiApCII6Wt6BA2hQ7ofTfkypV4cZpZqT3PY0-AK4Q7CEI8a1c5baHmw1CSskROEMUo5AwRo6bPSIkZAlFHXDu_XtDJQmMT0EHYc4Io_wMsIWsaieL4NGVptZVMN0qlxsfSB8s7CZIrWyOrHTByNVvwSj3uvyybnsBTjJZeHu5n13wcjd-Hk7D9GEyG_bTUEcJJaHGGYeYE6K1oZJmikTGciUjFVGOqFQJT5JIKay1RUZlCkYmMwoxw2PCCSVdcNN61678rK2vxLJ5wRaFXNmy9oKROEY4YQ3Ya0HtSu-dzcTa5UvptgJBsatK7KoSh6qawPXeXKulNb_4vpsG4C2wyQu7_Ucn-ovZ-K88bLO5r-z3ISvdh4h3dvG6mAj8NJjfp4O5oOQHpEWD4w</recordid><startdate>20030905</startdate><enddate>20030905</enddate><creator>Tietze, Lutz F.</creator><creator>Bell, Hubertus P.</creator><creator>Chandrasekhar, Srivari</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20030905</creationdate><title>Natural Product Hybrids as New Leads for Drug Discovery</title><author>Tietze, Lutz F. ; Bell, Hubertus P. ; Chandrasekhar, Srivari</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4853-c2f902933ccd5a5fb34de9ba4b45915ab89884bb2cce1dbfb04dfdb17d9639353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Animals</topic><topic>biological activity</topic><topic>Biological Factors - chemistry</topic><topic>Biological Factors - pharmacology</topic><topic>combinatorial chemistry</topic><topic>Drug Design</topic><topic>Drug Evaluation, Preclinical - methods</topic><topic>Humans</topic><topic>hybrids</topic><topic>Molecular Structure</topic><topic>natural products</topic><topic>Pharmaceutical Preparations - chemical synthesis</topic><topic>Pharmaceutical Preparations - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tietze, Lutz F.</creatorcontrib><creatorcontrib>Bell, Hubertus P.</creatorcontrib><creatorcontrib>Chandrasekhar, Srivari</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Angewandte Chemie International Edition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tietze, Lutz F.</au><au>Bell, Hubertus P.</au><au>Chandrasekhar, Srivari</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Natural Product Hybrids as New Leads for Drug Discovery</atitle><jtitle>Angewandte Chemie International Edition</jtitle><addtitle>Angewandte Chemie International Edition</addtitle><date>2003-09-05</date><risdate>2003</risdate><volume>42</volume><issue>34</issue><spage>3996</spage><epage>4028</epage><pages>3996-4028</pages><issn>1433-7851</issn><eissn>1521-3773</eissn><abstract>Natural products play an important role in the development of drugs, especially for the treatment of infections and cancer, as well as immunosuppressive compounds. However, the number of natural products is limited, whereas millions of hybrids as combinations of parts of different natural products can be prepared. This new approach seems to be very promising in the development of leads for both medicinal and agrochemical applications, as the biological activity of several new hybrids exceeds that of the parent compounds. The advantage of this concept over a combinatorial chemistry approach is the high diversity and the inherent biological activity of the hybrids.
Unlimited options: The synthesis of natural product hybrids by combining structurally different, naturally occurring compounds that exhibit high biological activities appears to be a promising approach to increase the number and diversity of substances for pharmacological testing. An example is the hybrid of estrone and (−)‐talaromycin (see picture).</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>12973759</pmid><doi>10.1002/anie.200200553</doi><tpages>33</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1433-7851 |
ispartof | Angewandte Chemie International Edition, 2003-09, Vol.42 (34), p.3996-4028 |
issn | 1433-7851 1521-3773 |
language | eng |
recordid | cdi_proquest_miscellaneous_73661287 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Animals biological activity Biological Factors - chemistry Biological Factors - pharmacology combinatorial chemistry Drug Design Drug Evaluation, Preclinical - methods Humans hybrids Molecular Structure natural products Pharmaceutical Preparations - chemical synthesis Pharmaceutical Preparations - chemistry |
title | Natural Product Hybrids as New Leads for Drug Discovery |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T20%3A28%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Natural%20Product%20Hybrids%20as%20New%20Leads%20for%20Drug%20Discovery&rft.jtitle=Angewandte%20Chemie%20International%20Edition&rft.au=Tietze,%20Lutz%20F.&rft.date=2003-09-05&rft.volume=42&rft.issue=34&rft.spage=3996&rft.epage=4028&rft.pages=3996-4028&rft.issn=1433-7851&rft.eissn=1521-3773&rft_id=info:doi/10.1002/anie.200200553&rft_dat=%3Cproquest_cross%3E73661287%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=73661287&rft_id=info:pmid/12973759&rfr_iscdi=true |